Previous / Next

[20120310. Complications of EMR/ESD (65): Bleeding (29) - aspirin (9) Compliance matters.]

Bleeding after ESD. 2022-10-16. ÀÌÁØÇà

The clinical relevance of response variability to antiplatelet therapy¶ó´Â review¿¡¼­ Èï¹Ì·Î¿î tableÀ» º¸¾Ò½À´Ï´Ù (link1, link2).

Table 1. Main variables affecting the pharmacodynamic response to aspirin
-------------------------------------
Lack of compliance
Underdosing
Interaction of other NSAIDs with COX-1
Increased platelet turnover
-------------------------------------

¿äÁ¡Àº clopidogrel drug response´Â ¿©·¯ ¿äÀÎÀÌ °ü¿©ÇϹǷΠȯÀÚº°·Î õÂ÷¸¸º°ÀÌÁö¸¸, ¾Æ½ºÇǸ° drug response´Â compliance¸¸ ÁÁÀ¸¸é ºñ±³Àû ÀÏÁ¤ÇÏ´Ù´Â °ÍÀÔ´Ï´Ù.


¾Æ½ºÇǸ° noncompliance¿¡ ´ëÇÑ Èï¹Ì·Î¿î ¹®ÇåÀ» Çϳª ´õ ¼Ò°³ÇÕ´Ï´Ù (Schwartz 2005). ¿ä¾àÀ» ¿Å±é´Ï´Ù.

"One hundred ninety patients with a history of myocardial infarction were evaluated using arachidonic acid-stimulated light aggregometry at 3 different time points: while receiving their usual daily aspirin, after not receiving aspirin for 7 days, and 2 hours after the observed ingestion of aspirin 325 mg. At the first time point, 17 patients (9%) failed to show aspirin inhibition of platelet aggregation, but 2 hours after observed aspirin ingestion, aspirin inhibition was observed in all but 1 patient."

¾Æ½ºÇǸ°À» Åõ¾àÇÏ¿´À¸³ª Ç÷¼ÒÆÇ ±â´ÉÀÌ Àß ¾ïÁ¦µÇÁö ¾ÊÀº ȯÀÚ¿¡°Ô °­Á¦·Î ¾àÀ» ¸ÔÀÎ ÈÄ ("observed aspirin ingestion") ´Ù½Ã °Ë»çÇÏ¿´´õ´Ï Ç÷¼ÒÆÇ ±â´ÉÀÌ Àß ¾ïÁ¦µÇ¾ú´Ù´Â °ÍÀÔ´Ï´Ù. ºñ½ÁÇÑ ³í¹®Àº ¾ó¸¶µçÁö ÀÖ½À´Ï´Ù. ¾àÀ» Àß ¸ÔÁö ¾Ê´Â ȯÀÚ°¡ ¸¹Àº ¸ð¾çÀÔ´Ï´Ù.


[Âü°í ÀÚ·á]

1) EndoTODAY ¿ÍÆĸ°

2) Ç×Ç÷¼ÒÆÇÁ¦ Antiplatelets - ³»½Ã°æ ȤÀº Á¶Á÷°Ë»ç Àü ¾Æ½ºÇǸ°, Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷À» °ÍÀΰ¡?

3) »õ·Î¿î Ç×ÀÀ°íÁ¦ New oral anticoagulant (NOAC)

4) Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦ Áß´Ü Áöħ (»ï¼º¼­¿ïº´¿ø 2011)

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà